Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sustained Tumor Control With MAPK Inhibition in BRAF V600–Mutant Adult Glial and Glioneuronal Tumors

4 Jun 2021

Abstract excerpt

Objective To assess whether RAF and MEK inhibitors (RAFi/MEKi) can provide long-term clinical benefit in adult patients with BRAF V600–mutant glial and glioneuronal tumors (GGNTs), we analyzed tumor response and long-term outcome in a retrospective cohort. Methods We performed a retrospective search in the institutional databases of 6 neuro-oncology departments for adult patients with recurrent or disseminated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Glioma Diagnosis and Treatment
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34088874
DOI: 10.1212/wnl.0000000000012330

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sustained Tumor Control With MAPK Inhibition in BRAF V600–Mutant Adult Glial and Glioneuronal TumorsPMID 34088874Read ↗

Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors.Semantic proximity Read ↗

Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma.Semantic proximity Read ↗

Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review.Semantic proximity Read ↗

Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with BRAF p.T599dup mutation.Semantic proximity Read ↗

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.Semantic proximity Read ↗

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain TumorsSemantic proximity Read ↗

A critical review of RAF inhibitors in BRAF-mutated glioma treatment.Semantic proximity Read ↗

Metastatic Low-Grade Glioma Successfully Treated in a Pediatric Patient With BRAF A598_T599insI Mutation.Semantic proximity Read ↗

Significant response to targeted therapy for Cervico-Medullary pediatric low grade glial tumors with BRAF V600E mutationSemantic proximity Read ↗

Challenges of targeting BRAF V600E mutations in adult primary brain tumor patients: a report of two cases.Semantic proximity Read ↗

Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma.Semantic proximity Read ↗

Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.